Why does R&D expenditure matter? How should executives manage their R&D investment? Should companies increase their R&D spending for greater returns? Should executives (and their company's shareholders) view R&D as an expense or an investment? With the recent publication of the 2007 UK R&D Scoreboard and the 2007 EU Scoreboards, which benchmark companies and countries on their R&D spend,
Investing in R&D: the how, where, when, and why, seeks to draw out the key lessons from the scoreboards' tables, to celebrate companies that are leaders in their field, and to help companies understand why R&D expenditure matters.
Following an introduction from Mike Tubbs on the latest evidence for the links between R&D and business performance, a panel of senior executives from leading R&D-intensive UK companies will give their insights, including:
- Richard Longdon, Chief Executive, AVEVA
- Bill Stuart-Bruges, Development Director, Sondex
- Brent Vose, VP of Oncology in Development, AstraZeneca
Following the presentations, a panel and audience discussion will explore the how, where, when, and why of investing in R&D.
Doors open for registration and coffee at 6pm. The meeting starts at 6.30pm with a drinks reception at 8pm.
Book by completing the online form and follow with payment online or by post. The meeting fee is £20 for R&D Society members and £40 for non-members, including refreshments and wine reception.
No comments:
Post a Comment